Shah Seema, Elmer Stacey, Grady Christine
Department of Bioethics, Clinical Center, and the Henry Jackson Foundation Liaison Office, Division of AIDS, National Institutes of Health, Bethesda, MD, USA.
Am J Public Health. 2009 Sep;99(9):1556-62. doi: 10.2105/AJPH.2008.157982. Epub 2009 Jul 16.
Despite recognition of the importance of posttrial access to antiretroviral therapy (ART), the implementation process has not been studied. We examined whether the National Institutes of Health (NIH) guidance document was being implemented in NIH-funded ART trials conducted in developing countries between July 2005 and June 2007. All of the 18 studies we identified had posttrial access plans for trial participants. More than 70% had specific mechanisms for posttrial access, but none guaranteed long-term sponsor funding after the trials. The plans reflected variation in local contexts and the uncertainty of predicting local conditions in the long term. The strength of the NIH guidance document may be that it encourages investigators to formulate plans in advance and to work with other stakeholders to provide access to ART.
尽管认识到试验后获得抗逆转录病毒疗法(ART)的重要性,但尚未对实施过程进行研究。我们调查了2005年7月至2007年6月期间在发展中国家开展的由美国国立卫生研究院(NIH)资助的ART试验中,NIH指导文件是否得到了实施。我们确定的18项研究均为试验参与者制定了试验后获取计划。超过70%的研究有试验后获取的具体机制,但没有一项能保证试验结束后有长期的资助方资金。这些计划反映了当地情况的差异以及长期预测当地状况的不确定性。NIH指导文件的优势可能在于它鼓励研究人员提前制定计划,并与其他利益相关者合作以提供ART获取途径。